


RealRate

PHARMACEUTICAL 2019



Arbutus Biopharma Corp Rank 56 of 363







PHARMACEUTICAL 2019





Arbutus Biopharma Corp Rank 56 of 363

The relative strengths and weaknesses of Arbutus Biopharma Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Arbutus Biopharma Corp compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Arbutus Biopharma Corp is the variable Other Revenues, reducing the Economic Capital Ratio by 17% points.

The company's Economic Capital Ratio, given in the ranking table, is 225%, being 188% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	129,229
Cost of Goods Sold	0
Intangible Assets	66,307
Liabilities, Current	11,239
Liabilities, Non-Current	0
Other Assets	22,224
Other Compr. Net Income	15
Other Expenses	17,507
Other Liabilities	16,432
Other Net Income	28,438
Other Revenues	5,945
Property and Equipment	10,145
Research and Development	57,934
Selling, General and Administrative Expense	16,002

Output Variable	Value in 1000 USD
Assets	227,905
Liabilities	27,671
Expenses	91,443
Revenues	5,945
Stockholders Equity	200,234
Net Income	-57,060
Comprehensive Net Income	-57,052
Economic Capital Ratio	225%

